Production of Recombinant Proteins in Suspension–Cultured Plant Cells
Authors:
- 1 January 2009
- book chapter
- Published by Springer Nature
- Vol. 483, 145-161
Abstract
Plants have emerged in the past decade as a suitable alternative to the current production systems for recombinant pharmaceutical proteins and, today their potential for low-cost production of high quality, much safer and biologically active mammalian proteins is largely documented. Among various plant expression systems being explored, genetically modified suspension-cultured plant cells offer a promising system for production of biopharmaceuticals. Indeed, when compared to other plant-based production platforms that have been explored, suspension-cultured plant cells have the advantage of being totally devoid of problems associated with the vagaries of weather, pest, soil and gene flow in the environment. Because of short growth cycles, the timescale needed for the production of recombinant proteins in plant cell culture can be counted in days or weeks after transformation compared to months needed for the production in transgenic plants. Moreover, recovery and purification of recombinant proteins from plant biomass is an expensive and technically challenging business that may amount to 80–94% of the final product cost. One additional advantage of plant cell culture is that the recombinant protein fused with a signal sequence can be expressed and secreted into the culture medium, and therefore recovered and purified in the absence of large quantities of contaminating proteins. Consequently, the downstream processing of proteins extracted from plant cell culture medium is less expensive, which may/does balance the higher costs of fermentation. When needed for clinical use, recombinant proteins are easily produced in suspension-cultured plant cells under certified, controllable and sterile conditions that offer improved safety and provide advantages for good manufacturing practices and regulatory compliance. In this chapter, we present basic protocols for rapid generation of transgenic suspension-cultured cells of Nicotiana tabacum, Oriza sativa and Arabidopis thaliana. These systems are powerful tools for plant-made pharmaceuticals production in highly controlled conditions.Keywords
This publication has 49 references indexed in Scilit:
- Endosperm tissue is good production platform for artificial recombinant proteins in transgenic ricePlant Biotechnology Journal, 2006
- PlantN-Glycan Processing Enzymes Employ Different Targeting Mechanisms for Their Spatial Arrangement along the Secretory PathwayThe Plant Cell, 2006
- Novel pathways for glycoprotein import into chloroplastsPlant Biotechnology Journal, 2006
- Plant biopharming of monoclonal antibodiesVirus Research, 2005
- Production and glycosylation of plant‐made pharmaceuticals: the antibodies as a challengePlant Biotechnology Journal, 2004
- Structural requirements for Arabidopsisβ1,2‐xylosyltransferase activity and targeting to the GolgiThe Plant Journal, 2003
- Bioproduction of Human Enzymes in Transgenic TobaccoaAnnals of the New York Academy of Sciences, 1996
- Control of in vivo proteolysis in the production of recombinant proteinsTrends in Biotechnology, 1992
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences, 1979
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970